LAT1 expression and micro-PET tracing in breast cancer

Abstract

Abstract: Objective

To investigate the expression of LAT1 gene in breast cancer and the value of micro-PTE tracing in detection of breast cancer.

Methods

The expressions of LAT1 mRNA and protein in breast cancer cells were analyzed.¹⁸F-FACBC was used as the imaging agent of micro-PET to detect breast cancer in nude mice.

Results

MCF-10A， a non-tumorigenic breast cell line， expressed low level of LAT1 mRNA and protein， while MCF-7， a malignant breast cell line， expressed high level of LAT1 mRNA and protein； The inhibiting of LAT1 inhibited the proliferation of breast cancer cells， and micro-PET with¹⁸F-FACBC imaging agent could effectively detected the breast cancer in nude mice.

Conclusion

LAT1 is highly expressed in breast cancer and can be used as a biomarker for the diagnosis of breast cancer， and¹⁸F-FACBC and LAT1 can be used to trace breast cancer with micro-PET.

Key words:L-type amino acid transporter 1,¹⁸F-fluorocyclobutane carboxylic acid,tracer detection,breast cancer

摘要： 目的

探讨乳腺癌L-型氨基酸转运蛋白1（LAT1）基因的表达及小动物正电子断层扫描仪（micro-PET）示踪检测乳腺癌的价值。

方法

检测乳腺癌细胞LAT1 mRNA和蛋白表达水平，以¹⁸F-氟环丁烷羧酸（¹⁸F-FACBC）为显像剂的micro-PET示踪检测裸鼠种植的乳腺癌。

结果

非致瘤乳腺细胞系MCF-10A表达低水平的LAT1 mRNA和蛋白，而恶性的癌细胞系MCF-7表达高水平的LAT1 mRNA和蛋白；抑制LAT1可抑制乳腺癌细胞增殖；以¹⁸F-FACBC为显像剂的micro-PET能有效检测裸鼠种植的乳腺癌。

结论

乳腺癌高表达LAT1，LAT1可作为诊断乳腺癌的生物标志物，¹⁸F-FACBC与LAT1可用于micro-PET示踪检测乳腺癌。

关键词:L-型氨基酸转运蛋白1,¹⁸F-氟环丁烷羧酸,示踪检测,乳腺癌

Xinliu SUN. LAT1 expression and micro-PET tracing in breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(1): 20-23.

孙新六. 乳腺癌LAT1表达及micro-PET示踪检测[J]. betway必威登陆网址（betway.com ）学报, 2022, 43(1): 20-23.

Figures/Tables9

分组	例数	LAT-1	t	P
MCF-10A	20	1.00 ± 0.05	35.570	< 0.001
MCF-7	22	4.21 ± 0.42

分组	例数	LAT-1	t	P
MCF-10A	20	1.00 ± 0.05	35.570	< 0.001
MCF-7	22	4.21 ± 0.42

分组	例数	LAT-1	t	P
MCF-10A	20	1.00 ± 0.02	12.450	< 0.001
MCF-7	22	2.62 ± 0.61

分组	例数	LAT-1	t	P
MCF-10A	20	1.00 ± 0.02	12.450	< 0.001
MCF-7	22	2.62 ± 0.61

分组	例数	摄取率（%）	t	P
MCF-10A	20	16.4 ± 4.6	11.410	< 0.001
MCF-7	22	36.2 ± 6.4

分组	例数	摄取率（%）	t	P
MCF-10A	20	16.4 ± 4.6	11.410	< 0.001
MCF-7	22	36.2 ± 6.4

分组	例数	存活率（%）	t	P
MCF-7	22	96.4 ± 3.6	14.250	< 0.001
MCF-7+BCH	22	62.4 ± 10.6

分组	例数	存活率（%）	t	P
MCF-7	22	96.4 ± 3.6	14.250	< 0.001
MCF-7+BCH	22	62.4 ± 10.6

分组	例数	免疫组化计分	t	P
T1 + T2	20	161 ± 23	9.945	< 0.001
T3 + T4	20	256 ± 36

分组	例数	免疫组化计分	t	P
T1 + T2	20	161 ± 23	9.945	< 0.001
T3 + T4	20	256 ± 36

References14

1	Li DM， Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis： potential therapeutic targets［J］. Breast Cancer Res Treat， 2011， 128（1）： 7.
2	Fotiadis D， Jeckelmann JM. The structure of the human 4F2hc-LAT1 heteromeric amino acid transporter［J］. Sci China Life Sci， 2019， 62（6）： 848.
3	Kongpracha P， Nagamori S， Wiriyasermkul P， et al. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 （LAT1）［J］. Pharmacol Sci. 2017； 133（2）： 96.
4	Lu XJ. The role of large neutral amino acid transporter （LAT1） in cancer［J］. Curr Cancer Drug Targets， 2019， 19（11）： 863.
5	Michaud L， Beattie BJ， Akhurst T， et al.¹⁸F-Fluciclovine （¹⁸F-FACBC） PET imaging of recurrent brain tumors［J］. Eur J Nucl Med Mol Imaging， 2020， 47（6）： 1353.
6	Higuchi K， Sakamoto S， Ando K， et al. Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma［J］. Sci Rep， 2019， 9（1）： 16776.
7	Pocasap P， Weerapreeyakul N， Timonen J， et al. Tyrosine-chlorambucil conjugates facilitate cellular uptake through L-type amino acid transporter 1 （LAT1） in human breast cancer cell line MCF-7［J］. Int J Mol Sci， 2020， 21（6）： 2132.
8	Nosaka K， Makishima K， Sakabe T， et al. Upregulation of glucose and amino acid transporters in micropapillary carcinoma［J］. Histol Histopathol， 2019， 34（9）： 1009.
9	Çelebi F. What is the diagnostic performance of¹⁸F-FDG-PET/MRI in the detection of bone metastasis in patients with breast cancer？［J］. Eur J Breast Health， 2019， 15（4）： 213.
10	He SM， Wang MW， Yang ZY， et al. Comparison of¹⁸F-FES，¹⁸F-FDG， and¹⁸F-FMISO PET imaging probes for early prediction and monitoring of response to endocrine therapy in a mouse xenograft model of ER-positive breast cancer［J］. Plos One， 2016， 11（7）： e0159916.
11	Karlberg A， Berntsen EM， Johansen H， et al.¹⁸F-FACBC PET/MRI in diagnostic assessment and neurosurgery of gliomas［J］. Clin Nucl Med， 2019， 44（7）： 550.
12	Greenwood HE， Nyitrai Z， Mocsai G， et al. High-Throughput PET/CT Imaging Using a Multiple-Mouse Imaging System［J］. Nucl Med. 2020； 61（2）： 292.
13	Göker M， Marcinkowski R， Van Bockstal M， et al.¹⁸F-FDG micro-PET/CT for intra-operative margin assessment during breast-conserving surgery［J］. Acta Chir Belg， 2020， 120（5）： 366.
14	Li P， Gui SB， Cao L， et al. Use of micro-positron emission tomography with¹⁸F-fallypride to measure the levels of dopamine receptor-D2 and¹⁸F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats［J］. Onco Targets Ther， 2016， 9： 2057.

[1]	Yuli ZHAO, Yixin ZHANG, Sen WANG, Huimin GUO, Li FENG.Smac mimics and treatment of breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(9): 702-706.
[2]	Yihao ZHAO, Dongbin ZHANG.Efficacy and safety of TCH neoadjuvant chemotherapy in Chinese patients with HER2 positive breast cancer： a Meta-analysis[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(9): 659-664.
[3]	Guimi SI, Changping SHAN.The progress of exosomal non-coding RNA in triple-negative breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(6): 461-465.
[4]	Yonghao LI, Mei ZHANG.Progress of organoid research and its application in breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(5): 381-387.
[5]	Zhao BI, Yongsheng WANG.The de-escalating strategy of local-regional management after neoadjuvant therapy in breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(4): 249-253.
[6]	Jiangang WANG, Yong HOU, Pengcheng WANG, Xinyuan LV.Dosimetric comparison of multi-criteria optimization and direct machine parameter optimization of intensity-modulated radiotherapy after radical mastectomy for left breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(4): 267-272.
[7]	Jian LI, Yan WANG.Study of TMEM65 expression on the prognosis of breast cancer patients[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(3): 198-204.
[8]	Binbin Li, Xintong Wang, Xinli Wang.Changes of related biological factors before and after neoadjuvant chemotherapy for breast cancer and analysis of related predictors of MP grading[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(12): 899-902.
[9]	Tihe Zhao, Dongxu Wang, Xiangqi Li.Clinical study on cardiotoxicity of different anthracycline containing chemotherapy regimens in patients with breast cancer[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(11): 823-828.
[10]	Dongxue Wang, Jingnan Wang, Qianqian Shen, Yuping Sun.Construction of a Nomogram prediction model for male breast cancer based on molecular typing： a SEER study[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(11): 816-822.
[11]	Jian Li, Yuna Liang.Construction of breast cancer protein risk prognosis model and identification of six key proteins[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(10): 721-728.
[12]	GU Ming-qiang.Clinical efficacy observation of local advanced breast cancer with weekly neoadjuvant chemotherapy[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(1): 49-52.